Lifeward (LFWD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 39% year-over-year to $6.1 million, driven by expanded Medicare coverage, strong ReWalk and AlterG sales, and robust U.S. and German pipelines.

• Gross profit margin improved to 36.2% (GAAP) and 42.5% (adjusted), with operational efficiencies from facility closures and manufacturing outsourcing targeting $3 million in annual savings.

• Net loss narrowed to $3.1 million ($0.35/share), a significant improvement from $7.5 million, with adjusted net loss at $4.0 million ($0.45/share).

• U.S. coverage base expanded to over 17,000 individuals, with a strong pipeline of 70 qualified ReWalk leads and 74 AlterG systems in backlog.

• Launched AlterG NEO and Neo Plus, generating 40 unit orders since June 2024 and driving incremental growth.

Financial highlights

• Q3 2024 revenue: $6.1 million (up 39% year-over-year); nine-month revenue: $18.1 million.

• Gross profit: $2.2 million (36.2% margin); adjusted gross profit: $2.6 million (42.5% margin).

• Operating expenses: $5.4 million (GAAP), $6.7 million (adjusted), both down year-over-year.

• Net loss: $3.1 million ($0.35/share), improved from $7.5 million ($0.88/share); adjusted net loss: $4.0 million ($0.45/share).

• Cash and equivalents: $10.7 million at quarter-end; cash used in operations was $4.5 million; no debt.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $25–26 million.

• Sequential revenue growth expected in Q4, with the highest quarterly revenue of the year anticipated.

• Path to profitability requires quarterly revenue of $12–13 million; current cash balance expected to support this if market growth aligns.

• Expects further gross margin improvement and continued cost reduction measures.

• May seek additional capital if revenue growth is insufficient to support cost structure.